Pfizer Inks Deal With FivePrime For Oncology, Diabetes Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration, to be managed by Pfizer's San Francisco-based biotech center, provides pharma giant with antibody targets.
You may also be interested in...
Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders
Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.
Centocor/Five Prime Deal Targets Protein Therapeutics For Osteoarthritis, Pulmonary Fibrosis
The research and licensing deal with protein-based biotech Five Prime could give the J&J company a therapy for regenerating cartilage.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.